Medical Device Recalls and Part 806
|
|
- Allison Hunt
- 6 years ago
- Views:
Transcription
1 Medical Device Recalls and Part 806 The Importance of Getting It Right Medmarc Insurance September 28, 2016 Steven Niedelman Lead Quality System & Compliance Consultant King & Spalding LLP 1700 Pennsylvania Ave., NW Washington, DC
2 General Recall Authority 21 CFR Part 7 - Guidance on Policy, Procedures and Industry responsibilities (21 CFR ) Defines what is/what is not a recall Defines classifications of recalls (Class I, II or III) Instructions on how to conduct a recall Guidance for firms (voluntary) Identifies FDA responsibilities Applies to all products FDA regulates Does not have the effect of law or regulation represents agency thinking on the matter
3 Unique Device Recall Authorities 21 CFR Part 806 (Medical Device Reports of Removals and Corrections) Prompted by Congressional hearings Reporting requirement for medical device manufacturers and importers to FDA within 10 business days of decision For situations that reduce a risk to health (class 1 & 2 recalls) 21 CFR Part 810 (Mandatory Medical Device Recalls) Rarely used since enactment in 1990 Class I situations when voluntary action not taken Provides opportunity for due process FDA may order a firm to recall product
4 Related Regulations Involving Recalls 21 CFR Part 820 (Quality System Regulation) Design control Product and process changes Validation of device and process changes Acceptance activities CAPA Complaint files and investigation Service activities 21 CFR 803 Medical Device Reporting 21 CFR (a)(3) Pre-Market Notification Significant changes are introduced 21 CFR PMA supplements 21 CFR Tracked devices
5 What is a Recall? Firm s removal or correction of a marketed product in violation of the Federal Food, Drug & Cosmetic Act and against which FDA would initiate legal action unless Voluntary action is undertaken by a firm when it determines a device is misbranded under 502 or adulterated under 501 of the Act Effective method to remove or correct consumer products in the market place More efficient and less costly alternative to FDAinitiated court action for removing violative products from the market (seizure) or import detention
6 Corrections and Removals Removal means the physical removal of a device from its point of use for repair, adjustment, relabeling, destruction or inspection. (21 CFR 806.2(i)) Correction means the report, modification, adjustment, relabeling, destruction, or inspection of a device without its physical removal. (21CFR 7.3(h))
7 Classes of Recalls Class I - Situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death. Reasonable Probability means that it is more likely than not that an event will occur Class II - Situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Class III - Situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
8 What Is Not a Recall Corrections and Removals, Part 806 is not required for: Market Withdrawal A firm s removal or correction of a distributed product which involves a minor violation that would not be subject to legal action by FDA or which involves no violation, e.g., normal stock rotation practices, routine equipment adjustments and repairs, etc. (21 CFR 7.3(j)) Stock Recovery A firm s removal or correction of a product that has not been marketed or that has not left the direct control of the firm, i.e., the product is located on premises owned by, or under the control of, the firm, and no portion of the lot has been released for sale or use. (21 CFR 7.3(k)) May include product at logistics and order fulfillment providers
9 Hypotheticals: Recall Definition Has a recall occurred? A sales rep receives the same complaint from two customers that the tip of the SuperSleek cannulae device fractured before surgery. He retrieves all SuperSleek cannulae that the customers have in stock and replaces them to address the complaints.
10 Hypothetical: Recall Definitions Has a recall occurred? VascFast realizes that it printed some inaccurate information regarding the manufacturing date and location on the packaging for several lots of SuperSleek cannulae and it sends a corrective letter and label to users. Removal or Correction? Correction!
11 Hypotheticals: Recall Definition Has a recall occurred? The misprinted packaging is identified while the affected devices are still in VascFast s warehouse. The manufacturer repackages all affected devices. Recall or Stock Recovery? Stock recovery!
12 How Firms Become Aware of Recalls Carefully monitor all data sources/feeders to determine shifts in trends and spikes Complaints Service reports - Parts usage Peer review literature Increase in NCRs Manufacturing issues Environmental issues New product evaluations Packaging complaints New information.
13 CDRH May Become Aware of Recalls Correction & Removal Reports FDA Inspections - Directed - Routine Consumer Complaints Adverse Event Reports Med Watch Reports MDRs (Medical Device Reports), OSB Information received by a firm, re-packager or distributor Competitors Internal Device Reviews MedSun Reports MRAs and other Country Agreements Radiation Product Reports Not all-inclusive!
14 Data Sources - Recalls: There is no magic number that may trigger the need for recall. A single catastrophic event may be enough! Potential severity of risk is important Resist rationalizing extent of use to minimize rate of events. Devices are expected to work correctly for their anticipated life. Manufacturers should establish end of life for devices. Expired warranties are not an excuse to not do the right thing! Don t depend upon physicians expertise to know what to do when the device fails not everyone is an expert! Use an established algorithm for triggering action and evaluation do not wait until till it is too late!
15 Triggering Events 21 CFR (a) Each device manufacturer or importer shall submit a written report to your FDA district office of any correction or removal of a device initiated by such manufacturer or importer if the correction or removal was initiated: 1. To reduce a risk to health posed by the device; or 2. To remedy a violation of the act caused by the device which may present a risk to health 21 CFR (b) The manufacturer or importer shall submit any required report within 10-working (business) days of initiating such correction or removal. That is 10 days from the decision to take action!
16 21 CFR Part 7.42: A Firm s Recall Strategy The recall strategy will include the following elements: Depth level in the distribution chain (i.e., consumers) Public Warning purpose is to alert the public that the product being recalled presents a serious hazard to health Effectiveness Checks verifies that all consignees at the recall depth specified have received notification and have taken appropriate action The recall strategy will specify the method(s) to be used to conduct the recall and the level of effectiveness checks that will be conducted.
17 Recall Strategy for Voluntary Recall Established Recall Procedures should include Recall Team: Names of persons who will have substantial involvement in recall. Recall Coordinator: Person with chief responsibility for recall. Product Involved: Product name, ID number, lot numbers. Volume of product affected: total boxes and number of units in each box. Earliest and most recent shipment dates. Problem Status: Description of problem that created need for the recall.
18 Voluntary Recall Strategy (cont d) Assessment of Hazards: Results of Health Hazard Evaluation Describe the likelihood of an injury occurring as a result of the problem and the seriousness of the injury likely to occur Consider benefit risk of removing implants Consider medical necessity situations Ease of Identifying Product Describe whether customers will be able to identify this lot of product easily. Degree to Which the Deficiency is Obvious Describe whether customers will know there is a defect in the product or whether product can be used without the customer noticing the defect.
19 Voluntary Recall Strategy (cont d) Assessment of Hazards (cont d): Degree to Which Product Remains Unused This should be an estimate based on the amount of product involved, the last shipment date, and the usage pattern (e.g., single use). 16 Continued Availability of the Product State whether current production is affected and whether shipment was stopped as a result of the problem. Is containment effective? Affected product on hold? In quarantine? Will a shortage situation be created? Is the product medically necessary? Need for repair parts and service replacements
20 Voluntary Recall Strategy (cont d) Investigation and Corrective Action: Describe the investigation into the cause of the problem. What the cause was determined to be. What corrective action was taken. Identify root cause! Product Reconciliation: Compare the amount of product released for distribution with the amount of product shipped. Discrepancies should be investigated and explained. Identification of Customers: State whether all customers who received the product have been identified.
21 Voluntary Recall Strategy (cont d) Product Action Strategy: Depth of Product Action State whether the recall will be to the user level or distributor level Will sub-recalls be needed? Conduct of Product Action Describe the planned actions. Indicate whether this will be a field correction or will the product be removed from the field and repaired, reconditioned or destroyed. Public Announcement State whether a public announcement is necessary and, if so, the form it will take.
22 Voluntary Recall Strategy (cont d) Communications: Type of Notification For each type of customer, describe the types of notifications to be used; e.g., certified mail, telegram, telephone, etc. Should communication to the user be through physicians who can best explain? Will patient monitoring be needed? Content of Communications For each type of communication, describe its contents.
23 Recall Communication Must state that the product is subject to recall and why. Further use of the product should stop immediately. - May require patient monitoring or physician visit Instructions on what to do with the recall product. Identify the product, size, lot number, serial number, etc. Explain reason for recall and hazard involved. Should not contain irrelevant qualifications or promotional materials. Should be reviewed by independent set of eyes. Follow FDA Model in Regulatory Procedures Manual (RPM). Ref:
24 Press Release Generally within discretion of recalling company, except Class I situations. Firms are expected to issue a press release in those situations. Should obtain FDA concurrence Should not be promotional FDA may issue its own press release for Class I recalls. Companies often issue press for Class II recalls. Don t forget to include copies of press releases on firm website.
25 Voluntary Recall Strategy (cont d) Disposition of Returned Product: Returned product should be either reconditioned or destroyed. If reconditioned, suggest discussing plan with FDA Assure violation is addressed in reconditioning Process followed should be documented. Be sure to maintain full accountability of product shipped vs. returned. Do not expect 100% accountability Make at least three good faith efforts to notify consignees and retrieve product (letters, visits, calls, etc.) Be sure to document all activities taken!
26 Voluntary Recall Strategy (cont d) Effectiveness Checks and Closure of the Recall Action: Describe when the recall will be considered completed. When most or all accounts have responded as to product on hand. - Maintain copies of letters and other written notifications. - Maintain response cards used for effectiveness checks. Document and quarantine returned product. Include those awaiting correction Determine when most or all product has either been reconditioned or destroyed notify FDA District Office Offer FDA opportunity to witness destruction» In developing destruction plans, be mindful of environmental issues, EPA, OSHA, etc.
27 Health Hazard Assessments Health Hazard Evaluation (HHE) or Health Risk Assessment (HRA) should be conducted to evaluate risk before any: Stock recoveries Safety alerts Market withdrawals Recalls HHEs/HRAs should be based on objective evidence of the device, its intended use and risk created by the situation. Should be evaluated by clinical staff who have expertise to effectively evaluate situation and assess risk. Firms should have established procedures requiring appropriate sign-off within their organization. At end of day, in case of indecision, one person must be identified as accountable.
28 Purpose of HHE and HRA Both are assessments of Risk to Health, follow the same process, and use the same documentation. HHE is a tool for classifying a voluntary recall by a firm. The evaluation guides FDA in determining the risk to the public from the defective product and appropriate actions for the firm and the FDA to take to protect public health. HRA is a tool for predicting possible harm that can come from a defective or malfunctioning device. The assessment helps the FDA and the firm determine if any actions are necessary such as recalling the devices or notifying the public about the risk.
29 Data Sources: Health Hazard Assessments Determine if issue was included in FMEAS: What was severity? Are known complaints consistent with what was evaluated in FMEA? (i.e., catastrophic outcome for a low or medium severity determination) Have unanticipated issues/complaints arisen? Is reevaluation necessary? Thorough, timely investigations are needed to determine how device was used and obtain any incidental information associated with use (e.g., capital equipment may require different investigation than single use product to take other factors into account)
30 Health Hazard Evaluation (HHE) CDRH will perform its own Health Hazard Evaluation (HHE), or utilize established precedents HHEs for similar problems/devices. This risk assessment will guide the Center in classifying the recall into one of the three classes and determine what actions are needed by the firm and FDA to protect the public health. Firms should be familiar with how FDA has classified similar situations in the past as a basis for what actions are expected to be undertaken. Search FDA s Recall Enterprise System (RES) and/or TPLC medical device data on
31 Defining the Risk Technical assessment of the defect defines likelihood of device failure. Clinical understanding of product defect and real life situations clarifies risk. Evaluation is made by FDA assuming no corrective action has been taken by the firm. Lack of reported injuries does not mean lower risk or recall classification. Be proactive do not wait for injuries and/or deaths to act!
32 Challenges in Class I Recalls Issues where manufacturers and FDA can disconnect: Defect is easily recognizable by the physician or Health Care Provider (HCP) Work-arounds are proposed and/or being done successfully by surgeons or other HCPs Such activities may distract physician attention from serious issues Other systems provide backup Inconvenience vs. risk of prolonging/rescheduling an interventional or diagnostic procedure Misuse by healthcare providers Experts have no problem Lack of expertise vs. design or labeling (instructions for use)
33 Silent Recalls: Common Fact Patterns Combining a product upgrade with a correction/removal. Distributing a market bulletin. Inform customers of recent device problems and advise of techniques to be used to help prevent those problems. Deploying sales representatives to inspect devices in the field to determine whether a known systemic problem is present. Exchanging defective devices for those customers who complain, without systematically removing the potentially defective devices from the field. Fix on fail Replacing known problematic parts during routine service.
34 Back Door Recalls: Sample Warning Letters Warning Letter to Penumbra, December 2009: [Y]our firm failed to submit its Report of Correction and Removal within the required ten day time frame as required by 21 CFR (b). Specifically, during our review of records related to distribution of complaints and medical device reports for your [device], it was revealed that from November 2008 you were aware of issues associated with the subject device. As a result, you decided to conduct an exchange action. Warning Letter to Medrad Inc., May 15, 2011: Medrad instituted corrective actions that should have been reported as recalls: Issued safety reminder to health care practitioners Upgraded software Released a disposable kit work-around
35 Service Activities Impact on Recalls Service is part of the quality system and not a separate business unit, therefore service records are quality records! Service may be a principal feeder of complaints and identifier of potential recall situations. Service activities should be closely trended based on complaints, parts usage, routine service and end of life. Service provides many opportunities for silent recalls to take place. Needs to be carefully monitored by the quality organization.
36 Service Activities Impact on Recalls (con t) Activities that may be recalls Specifically swapping out defective parts during next preventive maintenance service Making corrections and taking corrective actions during service visits Field service reps providing and installing parts on their own Fix on Fail situations Activities that may not be recalls Repairing or replacing known service parts during routine maintenance Includes parts that are identified for routine checking (e.g., belts, hoses, tensioners, etc.)
37 Hypotheticals: Recalls The manufacturer of a device incorporates a bulb in its on-off switch that has an expected life of two years. In their preventive maintenance schedule, these bulbs are replaced every two years. Isolated reports of bulbs have been failing at 22 and 23 months. Recall or Not? Not! Steady reports have been coming in about failures at 8-9 months Recall or Not? Recall!
38 Hypotheticals: Recalls Service has been receiving an increased number of complaints about back-up battery depletion. Upon return of the devices for service, the battery gauge indicates the battery is fully charged. Since this is the back up system, and there have not been any complaints, those batteries that are reported depleted are removed, recharged and reinstalled. Recall or Not? Recall!
39 Reporting of Corrections & Removals
40 Scope General Scope: 21 CFR Part 806 contains regulations governing the reporting of corrections and removals. Manufacturers and importers must promptly report corrections to devices and removals of devices when the action is taken to eliminate possible risk to health. Filing Window - Written reports must be submitted within 10 working days from the time the correction or removal action is initiated. Initiated means the date of decision to act. Amendments to Initial Reports: Where corrective action is extended to additional lots or batches of devices subject to the original action, an amendment to the initial report must be submitted to FDA within 10 working days of initiating the extended action. Many FDA Districts require filling out their own form which goes beyond 21 Part 806!
41 History Added authority under the Safe Medical Device Act of 1990, along with Mandatory Recall authority. First time the word recall appeared in the Food, Drug and Cosmetic Act! Congress saw need to require reporting of recall actions since medical device industry was not complying with recall guidance contained in 21CFR Part 7, and were not reporting recalls to FDA. Failure to report a recall that reduces a risk to health misbrands your device and subjects it to action.
42 Risk to Health Part 806 applies to the correction and removal of devices that pose or may pose a risk to health. Risk to health tracks the definitions for Class I and Class II recalls under the voluntary recall regulations. FDA defines the term to mean: Reasonable probability that the product will cause serious adverse health consequences or death, or that, The product may cause temporary or medically reversible adverse health consequences, or an outcome where the probability of serious adverse health consequences is remote. FDA equates serious adverse health consequences with serious injury. See 21 CFR 803.3(a)(1) [MDR definition].
43 Other Requirements 21 CFR Part 806 does not apply to correction or removal actions when a similar report is mandated under Parts 803, or 1004, however, most firms voluntarily file Part 806 reports with the District. Part 806 provides that the manufacturer, importer, or distributor must maintain an internal record of the correction or removal action even when a written report to FDA is not required. Internal record must be maintained for a period of two years beyond the expected life of the device. Record should include all communications regarding the correction or removal. These will likely be reviewed by FDA during inspections! Document! Document! Document!
44 Hypotheticals: Reporting Corrections and Removals Which of the following scenarios involve a recall that should be reported to FDA? 1. Scenario #1: VascFast replaces customers stocked SuperSleek cannulae with a new model that handles easier and also resolves a problem that made the cannula prone to breaking inside the aorta. 2. Scenario #2: Testing reveals a dangerous defect in one lot of the SuperSleek that has not yet reached customers but has been sent to distribution centers. The manufacturer replaces all the stock at the distribution centers Scenario # 1: Yes Scenario # 2; Possibly Yes - depending on the ownership of the product at the distribution centers. If it is no longer under the ownership and control of VascFast, it is reportable!
45 Final Enhancement vs. Recall Guidance Published October 15, 2014 Guidance is intended to clarify: When a change to a device constitutes a recall The difference between a device enhancement and a recall Whether the change needs to be reported to FDA under Part 806 Guidance focuses on core issues of distinguishing enhancements from recalls Recalls are conducted for changes to violative devices Enhancements are conducted for changes to non-violative devices Guidance is written in Q & A format with illustrative examples of scenarios that FDA considers to be a recall or enhancement The final guidance does not address when a change to a device requires a premarket submission
46 Final Enhancement vs. Recall Guidance Differentiating between violative from non-violative devices: Changes intended to resolve a failure to meet specifications or failure of the device to perform as represented would constitute a recall. Such devices are adulterated because they are of a lesser quality than they purport or are represented to possess. Changes to correct labeling that is false or misleading, fails to provide adequate directions for use or otherwise violates labeling requirements would generally be a recall. Labeling changes to non-violative devices (including additional warnings) would not be considered a recall.
47 FDA Draft Guidance: Factors to Consider Regarding Benefit Risk in Medical Devices June 16, 2016 Clarifies how CDRH considers the benefit and risk of medical devices in these contexts: Product scarcity if a product would be removed from the market in a recall or enforcement action Compliance and enforcement (e.g., appropriate regulatory response mechanism following an inspection that was non-compliant with QSR) Consideration of benefit-risk tradeoffs from patient perspective In a company s HHE, it opens opportunities to identify benefits of product at time of premarket approval/clearance in the product description
48 Draft Guidance Benefit and Risk What the draft guidance does and doesn t do: Does not change the regulatory classification of recalls or legal definitions of serious injury Does not change FDA s HHE strategy for categorizing the seriousness of harm to patients Does not resolve the issue of qualitative assessment vs. numerical probability calculation of likelihood of harm It does increase emphasis on duration of patient exposure to harm It does increase emphasis on estimation of harm upon patient exposure to a noncompliant manufacturer not just a nonconforming device
49 Summary There has been an increased focus on the importance of recalls throughout FDA. The number of recalls has seen a slight dip the past two years. Recalls are an effective and efficient way to manage a violative situation affecting adulterated or misbranded product in distribution. It is important that you know the requirements for device recalls and be timely in your reporting. It is important you are able to distinguish between a recall from an enhancement and be able to defend your position Remember, always act in the interest of public health it may reduce your risk and liability over time.
50 CDRH Recalls by Classification by Fiscal year Class 1 Class 2 Class 3
51 Questions? THANK YOU Steven Niedelman Lead Quality System & Compliance Consultant King & Spalding LLP 1700 Pennsylvania Ave., NW Washington, DC
Optimize Your Field Safety Corrective Actions Systems
Optimize Your Field Safety Corrective Actions Systems Patrick Caines, Ph.D. Baxter Healthcare 9 December 2016 1 Agenda International regulatory requirements and expectations for FSCA and recalls Developing
More informationMaintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success. Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist
Maintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist Agenda How an investigator should prepare and submit
More informationFDA s Final Rule on Medical Device Data Systems Signals Active Regulation of Data Communication Technologies
ADVISORY February 2011 FDA s Final Rule on Medical Device Data Systems Signals Active Regulation of Data Communication Technologies Contacts On February 15, 2011, the U.S. Food and Drug Administration
More informationChapter 7 RECALL PROCEDURES
Chapter 7 RECALL PROCEDURES This chapter contains the following sections: Section Topic Page 7-1 PURPOSE... 7-1 7-2 BACKGROUND... 7-1 7-3 SUMMARY OF FDA RESPONSIBILITIES AND PROCEDURES... 7-2 7-4 RECALL
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Devices Medical Devices Investigational Use Application IDE (21 CFR 812) Abbreviated IDE Exempt Pre-Market Approval Applications 510(k) Pre-marketing Notification (21 CFR 807(e))
More informationFDA Initiatives and Regulatory Trends for Life Sciences. Larry Spears President L. Spears Consulting
FDA Initiatives and Regulatory Trends for Life Sciences Larry Spears President L. Spears Consulting Before We Begin If you experience technical problems, please contact GoToMeeting Technical Support at
More informationRegulatory Overview of Proposed LDT Framework. FDA Concerns. Background. FDA Proposed Regulatory Approach. By Ben Berg, Meaghan Bailey, RAC
Regulatory Overview of Proposed LDT Framework By Ben Berg, Meaghan Bailey, RAC On July 31, 2014, the U.S. Food and Drug Administration (FDA or the Agency) notified both the Senate Committee on Health,
More informationRisk Management Services
Risk Management Services CRAFT BREWERY/DISTILLERY RECALL POLICY TABLE OF CONTENTS DEFINITIONS... 3 RECALL PROCEDURE... 3 Roles and Responsibilities...4 Recall Actions & Documentation...5 Decision to Recall...5
More informationPHARMA CONGRESS. Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments. October 28, 2008
PHARMA CONGRESS October 28, 2008 Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments Beverly H. Lorell, MD Senior Medical & Policy Advisor King & Spalding LLP Assessing
More informationGxP Auditing, Remediation, and Quality System Resourcing
GxP Auditing, Remediation, and Quality System Resourcing TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing
More informationGxP Auditing, Remediation, and Staff Augmentation
GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 5 GLP Auditing 6 Pharmacovigilance Auditing 6 Vendor/Supplier Auditing 7
More informationGxP Auditing, Remediation, and Staff Augmentation
GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing 8
More informationAAMI Quality Systems White Paper: Comparison of 21 CFR Part 820 to ISO 13485:2016 1
AAMI s White Paper Comparison of 21 CFR Part 820 to ISO 13485:2016 February 2017 AUTHORS Seb Clerkin, GMP Advisory Services Nicola Martin, Owner, Nicola Martin Consulting Jack Ward, Owner, Ward Sciences
More informationAssociation of American Railroads Quality Assurance System Evaluation (QASE) Checklist Rev. 1/12/2017
Company: Prepared By: Date: Changes from previous version highlighted in yellow. Paragraph Element Objective Evidence 2.1 Objective of Quality Assurance Program 2.2 Applicability and Scope 2.3 QA Program
More informationFDA Medical Device HFE Guidance
W H I T E P A P E R www.makrocare.com U S FDA has established a new Draft Guidance; Applying Human Factors and Usability Engineering to Medical Devices to Optimize Safety and Effectiveness in Design. Manufacturers
More informationIncorporating Risk Management into Complaint and Service Experience. Presented by: Richard J. DeRisio, M.S. Kinetic Concepts, Inc.
Incorporating Risk Management into Complaint and Service Experience Presented by: Richard J. DeRisio, M.S. Kinetic Concepts, Inc. 1 Management of Complaint and Service Experience A Compliance Headache?
More information21 CFR Ch. I ( Edition) Personnel Design controls Identification Traceability.
Pt. 820 device together with an explanation of the basis for the estimate; (iv) Information describing the applicant s clinical experience with the device since the HDE was initially approved. This information
More informationMedical Device Purchasing Controls Challenges of Compliance in a World Market June, 2013 OMTEC
Medical Device Purchasing Controls Challenges of Compliance in a World Market June, 2013 OMTEC - 2013 Quality Business Acceptance Activities 1 ..FDA Across the Globe.. 2 ..Warning Letters and FDA 483 update..
More informationPolicy and Procedure Manual
Policy and Procedure Manual Finance and Accounting Procurement Services F-PS-01.00 SUBJECT/TITLE: PURPOSE: DEFINITION: STATEMENT OF VENDOR OWNED INVENTORY (CONSIGNMENT) POLICY This policy will cover all
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 8 Inspections, Compliance, Enforcement, and Criminal Investigations Lupin Limited 5/7/09 Department of Health and Human Services Public Health Service Food and Drug Administration CENTER FOR
More informationBest Practices: Integration of Risk Management and Corrective and Preventive Action
Best Practices: Integration of Risk Management and Corrective and Preventive Action Presented by: Norman L. Collazo Worldwide Director of Strategic Quality Cordis Corporation, a Johnson & Johnson company
More informationClarifying digital health and software regulation: FDA releases three new guidance documents
Clarifying digital health and software regulation: FDA releases three new guidance documents December 15, 2017 On December 7, 2017, the Food and Drug Administration (FDA or the Agency) released three guidance
More informationFDA. Design of Biomedical Devices and Systems, 2nd Edition, King & Fries, CRC Press, 2009.
FDA www.fda.gov Design of Biomedical Devices and Systems, 2nd Edition, King & Fries, CRC Press, 2009. ABOUT US FDA's Mission Statement The FDA is responsible for protecting the public health by assuring
More informationDe Novo Classification Process (Evaluation of Automatic Class III Designation) Guidance for Industry and Food and Drug Administration Staff
De Novo Classification Process (Evaluation of Automatic Class III Designation) Guidance for Industry and Food and Drug Administration Staff Document issued on October 30, 2017. The draft of this document
More informationFood and Drug Administration, HHS Pt Sec Scope Definitions Quality system.
Food and Drug Administration, HHS Pt. 820 authorized designee. If, however, a physician in an emergency situation determines that approval from an IRB cannot be obtained in time to prevent serious harm
More informationGMPs: Distribution Centers
SkillsPlus International Inc. The On-Site Series GMPs: Distribution Centers Learn to apply the GMP regulations as they relate to distribution center operations! FDA Past, Present, and Future and opener
More informationPresentation of Capabilities Reverse Logistics
Presentation of Capabilities Reverse Logistics Woodfield Distribution, LLC v081617 Reverse Logistics About Us Description of Services Reverse Distribution Channels DSCSA/Sustainability About Us WDSrx Woodfield
More informationRevision. Quality Manual. Multilayer Prototypes. Compliant to ISO / AS9100 Rev C
1 of 29 Quality Manual Multilayer Prototypes Compliant to ISO 9001-2008 / AS9100 Rev C This Quality Manual sets forth the quality system policies and Defines compliance with the ISO 9001-2008 SAE AS 9100
More informationPART 820 QUALITY SYSTEM REGULATION. 21 CFR Ch. I ( Edition)
814.126 (b) Withdrawal of IRB approval. A holder of an approved HDE shall notify FDA of any withdrawal of approval for the use of a HUD by a reviewing IRB within 5 working days after being notified of
More informationDrag Chain Conveyor Installation and Operation Manual
Drag Chain Conveyor Installation and Operation Manual Material Handling Equipment Sales, Incorporated 310 S. Section Line Rd Delaware, OH 43015 Phone: (989) 430-4005 Fax: (740) 363-9004 WARRANTY MATERIAL
More informationISPE Annual Meeting 29 October 1 November 2017 San Diego, CA
Post Marketing Safety Reporting (PMSR) Challenges and Successful Practices for Combination Products Objective Session Goals Summary of the final rule Interpretation for combination products approved as
More informationThe interface between Good Clinical Practice and Good Manufacturing Practice
1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who
More informationGUIDE TO INSPECTIONS OF QUALITY SYSTEMS
FOOD AND DRUG ADMINISTRATION GUIDE TO INSPECTIONS OF QUALITY SYSTEMS 1 1 August 1999 2 Guide to Inspections of Quality Systems This document was developed by the Quality System Inspections Reengineering
More informationCGMP and Postmarketing Safety Reporting Requirements for Combination Products
CGMP and Postmarketing Safety Reporting Requirements for Combination Products GMP by the Sea August 29, 2017 Mark D. Kramer Regulatory Strategies, Inc. 1 Definition of a Combination Product A combination
More informationApproved Supplier Guidance
Approved Supplier Guidance Administrative Office: 2420 W. R. Larson Rd. San Antonio, Texas 78261 (210) 384-3484 FAX (830) 438-2309 D&D Machinery and Sales Inc. Approval by: Original copy retained in D&D
More informationJI) C~ ~~cl MAR WARNING LETTER VIA FEDERAL EXPRESS
JI) C~ ~~cl DEPART7VIENT OF HEAI:II-I & I-ICTNLAN SERVICES Public Health Service MAR 2 1 2001 Food and Drug Administration Center for Devices and Radiological Health 2098 Gaither Road WARNING LETTER Rockvilfe,
More informationPharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act
Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance U.S. Department of Health and Human Services Food and Drug Administration Center for
More informationRev A. Vendor Compliance Manual
9004160 Rev A Vendor Compliance Manual Using the Vendor Compliance Manual This manual is designed to provide you with Automation Products Group, Inc. s (APG s) supply chain requirements. Please carefully
More informationBHG Operational Awareness Program May 8, 1998 Hazard Identification, Analysis, Control and Abatement Revision 0 Page 1 of 10
Page 1 of 10 HAZARD IDENTIFICATION, ANALYSIS, CONTROL, AND ABATEMENT 1.0 SCOPE This Performance Assessment Guide for Hazard Identification, Analysis, Control, and Abatement will be used to carry out the
More informationEU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
More informationUnderstanding FDA Guidance On Connected Medical Devices
Portfolio Media. Inc. 111 West 19 th Street, 5th Floor New York, NY 10011 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Understanding FDA Guidance On Connected Medical
More informationCODE OF BUSINESS CONDUCT AND ETHICS. FRONTIER AIRLINES, INC. Adopted May 27, 2004
1. Introduction CODE OF BUSINESS CONDUCT AND ETHICS FRONTIER AIRLINES, INC. Adopted May 27, 2004 The Board of Directors adopted this Code of Business Conduct ( Code ) to establish basic legal and ethical
More informationWhite Paper: Food Safety Enforcement and Inspection Actions and Terminology
USDA-FNS White Paper: Food Safety Enforcement and Inspection Actions and Terminology MULTI-AGENCY TASK FORCE FOR USDA FOODS USDA, Food and Nutrition Service This document provides an overview of basic
More informationSupplier Quality Manual
ALLIANCE ELECTRONICS DISTRIBUTOR Supplier Quality Manual 22412 Gilberto Rd. Rancho Santa Margarita, CA 92688 INTRODUCTION Welcome to Alliance Electronics Distributor (AED) Alliance Electronics Distributor
More informationGuidance for Industry
Guidance for Industry Notification to FDA of Issues that May Result in a Prescription Drug or Biological Product Shortage DRAFT GUIDANCE This guidance document is being distributed for comment purposes
More informationOVERVIEW OF THE PREQUALIFICATION OF IN VITRO DIAGNOSTICS ASSESSMENT
P r e q u a l i f i c a t i o n T e a m - D i a g n o s t i c s OVERVIEW OF THE PREQUALIFICATION OF IN VITRO DIAGNOSTICS ASSESSMENT WHO Prequalification of In Vitro Diagnostics NOTE: Additional technical
More informationISO 22000:2005 Standard INTERNATIONAL STANDARDS REGISTRATIONS
ISO 22000:2005 Standard Food Safety Management System INTERNATIONAL STANDARDS REGISTRATIONS 3.1 FOOD SAFETY concept that food will not cause harm to the consumer when it is prepared and/or eaten according
More informationANSI What providers need to know. ANSI 5010 What providers need to know
ANSI 5010 What providers need to know. 1 What does ANSI 5010 mean to your practice or facility? The new transaction set means there will be less ambiguity in the implementation guides. You will have one
More informationProduct safety and conformity in the automotive supply chain in the case of product nonconformities 1 st Edition, February 2018 Online-Download-Docume
Quality Management in the Automotive Industry Product safety and conformity in the automotive supply chain in the case of Product nonconformities 1 st Edition, February 2018 Online-Download-Document Product
More informationGlobal Product Safety: Trends & Updates CANADA. Teresa Dufort December 4, 2012 McMillan LLP
Global Product Safety: Trends & Updates CANADA Teresa Dufort December 4, 2012 McMillan LLP What Hasn t Changed CCPSA Prohibitions Outline Mandatory Incident Reporting What Is New? New Guidance on Mandatory
More informationCREATIVE PRODUCTS WARRANTY RETURN POLICY
CREATIVE PRODUCTS WARRANTY RETURN POLICY 1. GENERAL INFORMATION Prior to warranty holder ( You ) making any warranty service return of a Creative product ( Product ), You are strongly advised to first:
More informationQUALITY MANUAL DISTRIBUTION. Your Logo Here. Page 1 1 of 57. Rev.: A
Page 1 1 of 57 President Design Engineering Production Production Engineering Materials Control Purchasing Service Marketing Sales Contracts Human Resources Quality Assurance Quality Control Production
More informationGUIDELINES ON GOOD DISTRIBUTION PRACTICES FOR PHARMACEUTICAL PRODUCTS
DRAFT VERSION GUIDELINES ON GOOD DISTRIBUTION PRACTICES FOR PHARMACEUTICAL PRODUCTS Published on the website of www.cdsco.nic.in on 10/01/2013 Notification The following draft guideline is hereby published
More informationCSA Group Products, Processes and Services Scheme
1. CONTACT CSA CSA Group Products, Processes and Services Scheme 1.1 Getting started is easy. There are three ways to contact us: Call 866 797 4272 Email client.services@csagroup.org Complete a request
More informationEPICOR, INCORPORATED QUALITY ASSURANCE MANUAL
EPICOR, INCORPORATED QUALITY ASSURANCE MANUAL Revision: 6 Date 05/18/09 EPICOR, INCORPORATED 1414 E. Linden Avenue P.O. Box 1608 Linden, NJ. 07036-0006 Tel. 1-908-925-0800 Fax 1-908-925-7795 Table of Contents:
More informationCITY AND BOROUGH OF WRANGELL WATER SHORTAGE MANAGEMENT PLAN
CITY AND BOROUGH OF WRANGELL WATER SHORTAGE MANAGEMENT PLAN SECTIONS: Findings Purpose and Intent Waste of Water Prohibited Authorization Action for Hydrological Shortage Action for Emergency Shortage
More informationDefinitions contained in the above mentioned Specifications and Industry Standards are applicable herein.
1. SCOPE Quality Specification TEC-1019 12 Jul 11 Rev C All Paragraphs Revised Global Quality Management System Supplement for the Aerospace Industry Model, AS 9100 (C) 1.1. Content This specification
More informationGUIDELINES ON RECALL AND RAPID ALERT SYSTEM FOR DRUGS (Including Biologicals & Vaccines)
GUIDELINES ON RECALL AND RAPID ALERT SYSTEM FOR DRUGS (Including Biologicals & Vaccines) VERSION : 2017 Document No : CDSCO/RRAS Ver. : 00 Effective Date : 23/11/2012 Central Drugs Standard Control Organisation
More informationSuccessfully Managing Product Recalls and Withdrawals
GROCERY MANUFACTURERS ASSOCIATION Successfully Managing Product Recalls and Withdrawals Co-Editors: Melinda M. Hayman, Ph.D. and Lloyd R. Hontz Fourth Edition 2014 Successfully Managing Product Recalls
More informationThe Impact of Quality Culture on Quality Risk Management. FDA Perspective on Quality Culture; how it Impacts Risk Management
The Impact of Quality Culture on Quality Risk Management FDA Perspective on Quality Culture; how it Impacts Risk Management Teresa Gorecki Practice Lead Compliance Architects Agenda The WHAT Definitions
More informationSAI Global Full Service Team
General information regarding elements of the certification process is described below. A degree of flexibility and options in the certification process are available so please feel free to contact us
More informationExpanded Access and the Individual Patient IND
Expanded Access and the Individual Patient IND Research Wednesdays April 26, 2017 Erika Segear Johnson, PhD, RAC Associate Director of Regulatory Affairs Office of Regulatory Affairs and Quality Office
More informationClothes Washer Verification Program Procedural Guide February 2012 Version 1.0
Clothes Washer Verification Program Procedural Guide February 2012 Version 1.0 p 1 p 1 Sponsor: Association of Home Appliance Manufacturers 1111 19 th St. NW Suite 402 Washington, DC 20036 Administrator:
More informationMEASURE FOR MEASURE: QUALITY METRICS
MEASURE FOR MEASURE: QUALITY METRICS PDA Midwest Chapter Dinner Meeting, Northbrook, IL-9 November 2017 Felicia Ford-Rice, Director, Strategic Compliance 2017 PAREXEL INTERNATIONAL CORP. AGENDA Robust
More informationPharmacovigilance and the Generic Industry
Pharmacovigilance and the Generic Industry Presented by Joan Janulis, RAC Vice President Lachman Consultant Services Inc. 2015 Lachman Consultant Services, Inc. All rights reserved. Legal Notice The information
More information2015 > Soft Computer Consultants, Inc. 4/30/15
Page 1 of 7 U.S. Food and Drug Administration Protecting and Promoting Your Health Soft Computer Consultants, Inc. 4/30/15 SHARE (HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTP%3A%2F%2FWWW.FDA.GOV%2FICECI%2FENFO
More informationUPPLIER ANUAL. Issued: 01 Aug 13
UPPLIER ANUAL Issued: 01 Aug 13 Table of Contents Our Company 3 Our Vision 3 Scope and Purpose 4 Responsibilities 4 General Expectations and Requirements 5 Supplier Quality Management System 6 Supplier
More informationMDSAP AUDIT PROCESS. A Manufacturer s Perspective. Connie Hoy EVP Regulatory Affairs Cynosure, Inc.
MDSAP AUDIT PROCESS A Manufacturer s Perspective Connie Hoy EVP Regulatory Affairs Cynosure, Inc. Cynosure Located in Westford, MA Largest manufacturer of Medical Lasers Second location in Hicksville,
More informationSub-Part I Implementation. Bill Byrnes Champion Enterprises, Inc.
Sub-Part I Implementation Bill Byrnes Champion Enterprises, Inc. The Sub Part I Process Purpose What is Sub-Part I from the grass roots perspective Topics How do we teach Champion plants to implement Sub-Part
More informationOver the last ten years, Congress has appropriated hundreds
Information Bulletin #23 RM RISK MANAGEMENT Series Jacqueline C. Leifer, Esq. Adam J. Falk, Esq. Feldesman Tucker Leifer Fidell LLP Washington, DC For more information contact: Betsy Vieth National Association
More informationFAIRFIELD GLOBAL SUPPLIER QUALITY PROGRAM
FAIRFIELD GLOBAL SUPPLIER QUALITY PROGRAM 1 QA.101 rev. 3-2012 PURPOSE OF THIS STANDARD Fairfield is committed to continuous product quality improvement. Our management team is convinced that only with
More informationProduct Recall Manual
Preparation Is Essential A recall happens nearly every day, but it is easy to think that it can t happen to you. The reality is that we are all at risk of becoming involved in a recall and once you are
More informationResponding to an FDA 483
Responding to an FDA 483 Jim Melancon VP, Associate General Counsel BioScrip, Inc. Marc Stranz, PharmD Healthcare Consultant Disclosure The speakers declare no conflicts of interest or financial interest
More informationRecall Implementation and Effectiveness: New Guides and Standards By Kenneth Ross. Introduction
Recall Implementation and Effectiveness: New Guides and Standards By Kenneth Ross Introduction In the last issue of Strictly Speaking, I wrote on recall preparedness. In that article, I briefly mentioned,
More informationDRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Document issued on: December 27, 2011
Draft Guidance for Industry and Food and Drug Administration Staff The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)] DRAFT GUIDANCE This guidance document is being
More informationINS QA Programme Requirements
Specification Date: 20/3/17 INS QA Programme Requirements UNCONTROLLED WHEN PRINTED Author: J Cooch AUTHORISATION Date: 20/3/17 A Brown Owner: J Cooch (Signature) N.B. only required for hard copy If issued
More informationPage 1 of 11 www.osha.gov A-Z Index: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Search OSHA Regulations (Standards - 29 CFR) Guidelines for Employer Compliance (Advisory) - 1910.1200 App E Regulations
More informationDue diligence in the European medical devices industry
Due diligence in the European medical devices industry Alison Dennis, Reed Smith LLP www.practicallaw.com/0-205-5707 As the medical devices industry is highly regulated, determining a target company's
More informationInvestigator-Initiated INDs
Investigator-Initiated INDs Marjorie Small, RN, CCRC Office of Clinical Research 23 May 2011 PPHS/IRB Research Grand Rounds Outline of Presentation I. What is an IND? II. Code of Federal Regulations III.
More informationQM-1 QUALITY MANAGEMENT SYSTEMS MANUAL. Revision 10
QM-1 QUALITY MANAGEMENT SYSTEMS MANUAL Revision 10 Page: 1 of 54 TABLE OF CONTENTS 1. DOCUMENT REVISION HISTORY... 5 2. INTRODUCTION... 6 2.1 Purpose... 6 2.2 Scope... 7 Figure 1: Sequence and Interaction
More information*NOTIFY THE DEPARTMENT IN WRITING OF ANY UPDATES
APPLICATION FOR A PERMIT UNDER CHAPTER 499, FLORIDA STATUTES Florida Department of Business and Professional Regulation Drugs, Devices, and Cosmetics Program 1940 North Monroe Street, Tallahassee FL 323990783
More informationOverview of the Drug Supply Chain Security Act. GPhA Fall Technical Conference Bethesda, MD October 28, 2014
Overview of the Drug Supply Chain Security Act GPhA Fall Technical Conference Bethesda, MD October 28, 2014 Disclaimer This presentation contains a summary of the opinion and perspective from GPhA member
More informationConducting Effective Internal Investigations. From Workplace Harassment to Criminal Conduct and Everything in Between
Conducting Effective Internal Investigations From Workplace Harassment to Criminal Conduct and Everything in Between Presenters Christopher G. Keim Partner, Management Committee Chris is a trial lawyer
More informationIntermaritime Certification Services (ICS) QUALITY MANAGEMENT SYSTEM INSTRUCTIVE FOR ISM-CODE
1.0 TITLE: 2.0 OBJECTIVES This Instructive reflect, as applicable, the IMO Resolution A.1022 (26) "Guidelines on the Implementation of the ISM-Code by Administrations" and the IMO Resolution A.741 (18)
More informationAdvertising and Marketing Genetic Tests New Pathways or Old Roads?
Advertising and Marketing Genetic Tests New Pathways or Old Roads? Kathleen M. Sanzo, Morgan Lewis FDLI Advertising & Promotion Conference Wednesday, September 28, 2016 Context for Use of Genetic Tests
More informationSummary of TL 9000 R4.0 Requirements Beyond ISO 9001:2000
This summary identifies the additional TL 9000 Release 4.0 requirements beyond those stated in ISO 9001:2000. See the TL 9000 R4.0 Handbook for the actual TL 9000 R4.0 requirements. ISO 9001:2000 section
More informationTheodore Sullivan Partner Quarles & Brady LLP (Washington, DC)
Rachael Pontikes Partner Duane Morris LLP (Chicago, IL) Theodore Sullivan Partner Quarles & Brady LLP (Washington, DC) Moderator: Brian Malkin Counsel Arent Fox LLP (Washington, DC) 1 Legality of Animal
More informationCase Report from Audit Firm Inspection Results
Case Report from Audit Firm Inspection Results July 2014 Certified Public Accountants and Auditing Oversight Board Table of Contents Expectations for Audit Firms... 1 Important Points for Users of this
More informationFor Use By Certification Bodies Performing SAAS Accredited SA8000:2014 Certification Audits
1 2 3 4 5 6 SAAS Procedure 201A Accreditation Requirements 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 For Use By Certification Bodies Performing SAAS Accredited SA8000:2014 Certification Audits October
More informationFSC36 SAFE FEED/SAFE FOOD GUIDANCE DOCUMENT
FSC36 SAFE FEED/SAFE FOOD GUIDANCE DOCUMENT FSC36 Safe Feed/Safe Food (www.safefeedsafefood.org) is a facility certification program for the American Feed Industry Association (www.afia.org) Version 7.0
More informationBIOMEDICAL EQUIPMENT CUSTOMER DEPARTMENT REFERENCE MANUAL
BIOMEDICAL EQUIPMENT CUSTOMER DEPARTMENT REFERENCE MANUAL Biomedical Engineering Department 747 52 nd Street, Oakland CA 94609 510-428-3610 (After Hours pager # 7566) THE BIOMEDICAL EQUIPMENT REFERENCE
More information4. RELATED DOCUMENTS AND FORMS 4.1. AS ISO Cambridge Valley Machining, Inc. QMS procedures, including, but not limited to:
Approved By: Purchasing Manager Candice Lane (signature on file) Date: 5/26/17 Approved By: Process Owner James D. Moore (signature on file) Date: 5/26/17 1. PURPOSE 1.1. To define Cambridge Valley Machining,
More informationNovember 12, The Law of Islamic Republic of Afghanistan Draft Law on Industrial Designs
November 12, 2012 The Law of Islamic Republic of Afghanistan Draft Law on Industrial Designs Industrial Designs Chapter One General Provisions Article NO Topic Page Article 1: Basis ------------------------------------------------------------------
More informationDeveloping a Robust Quality System to Assure Data Integrity
Developing a Robust Quality System to Assure Data Integrity Maryann Gribbin Chief Compliance Officer, Faith & Royale Consultants Co-Chair PDA Data Integrity Task Force Data Integrity Facts or information
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More informationCorrespondence Between ISO 13485:2016 and 21 CFR Part 820 QMS Requirements
Correspondence Between and 21 CFR Part 820 QMS Requirements 10411 Corporate Drive, Suite 102, Pleasant Prairie, WI 53158 262.842.1250 262.842.1240 info@rcainc.com rcainc.com 2 4 Quality Management System
More informationSpecification for Quality Programs for the Petroleum, Petrochemical and Natural Gas Industry (Draft 10)
Specification for Quality Programs for the Petroleum, Petrochemical and Natural Gas Industry (Draft 10) ANSI/API SPECIFICATION Q1 NINTH EDITION, XXXX 2012 EFFECTIVE DATE: XXXX 2012 + 6 Months \iii Contents
More informationwas published. February 21, 2017
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers
More informationCanadian Market Surveillance Model on Consumer Product Safety
OAS Management of Market Surveillance Systems on Consumer Product Safety May 23, 2012 Washington DC, USA Canadian Market Surveillance Model on Consumer Product Safety Keilee Meraw Consumer Product Safety
More informationSUPPLIER GUIDELINES MANUAL
1.0 INTRODUCTION 1.1 This guidelines manual defines the minimum requirements for Supreme Machined Products Co.; Inc. LTD (to be referenced as Supreme throughout the document) Supplier s and does not supersede
More information